Skip to main content

AstraZeneca PLC ADR Value Stock - Dividend - Research Selection

Astrazeneca

ISIN: US0463531089 , WKN: 886715

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


AstraZeneca PLC (AZN) Q4 2024 Earnings Call Transcript

2025-02-06
AstraZeneca PLC (NASDAQ:AZN) Q4 2024 Earnings Conference Call February 6, 2025 6:00 AM ETCompany ParticipantsPascal Soriot – Executive Director and Chief...

AstraZeneca PLC 2024 Q4 - Results - Earnings Call Presentation

2025-02-06
The following slide deck was published by AstraZeneca PLC in conjunction with their 2024 Q4 earnings call.

Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data

2025-02-05
Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients with PH-HFpEF. Explore more details here.

ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data

2025-02-02
ORIC's ORIC-533 was promising but failed in trials, leaving ORIC-114 and ORIC-944 as key pipeline assets. Read why I am neutral on ORIC stock.

Buy 1 Safer Ideal January Dog Of 35 Barron's Pro-Picked 2025 Dividends

2025-01-31
Get insights into top dividend stock picks for 2025 from Barron’s Roundtable, with potential gains ranging from 19.46% to 35.09%.

ClearBridge International Growth ADR Portfolios Q4 2024 Commentary

2025-01-30
The benchmark MSCI EAFE Index declined 8.11% in the quarter while the MSCI Emerging Markets Index fell 8.01%. Read more here.

Templeton Foreign Fund Q4 2024 Commentary

2025-01-29
Signals from the US Federal Reserve that it intends to be cautious about further rate cuts helped drive global equities collectively lower in December 2024.

BGY: Strong Dollar Weighs On International Markets, But Don't Ignore Them

2025-01-29
The BlackRock Enhanced International Dividend Trust offers high income and international diversification. U.S. equities are richly valued, making diversification through this CEF appealing.

Franklin International Growth Fund Q4 2024 Commentary

2025-01-29
Unlike in the U.S., where moderating inflation has been accompanied by resilient GDP growth, Europe and the U.K. continue to face recession risks. Read more here.

Baron International Growth Fund Q4 2024 Shareholder Letter

2025-01-29